Ensysce Biosciences is a pioneering pharmaceutical company focused on addressing the opioid abuse and overdose crisis through innovative drug development. Operating in the biotech and pharmaceutical markets, Ensysce serves healthcare providers, patients, and regulatory bodies by developing safer opioid analgesics. The company's core business model revolves around its proprietary prodrug technology, which modifies the drug substance at a chemical level to prevent abuse and overdose. This approach differentiates Ensysce from traditional methods that alter the drug formulation, which have proven ineffective. Ensysce generates revenue through the development and commercialization of its unique opioid products, aiming to launch the first new class of opioid analgesics in decades. The company leverages its expert team, including leaders in emergency medicine and toxicology, to bring these groundbreaking drugs to market.

Keywords: opioid analgesics, prodrug technology, abuse prevention, overdose prevention, pharmaceutical innovation, biotech, healthcare, drug development, emergency medicine, toxicology.